Barinthus Biotherapeutics (formerly known as Vaccitech) is a T-cell immunotherapy company developing products to treat and prevent cancer and infectious diseases. Its therapeutic programs include the treatment of chronic hepatitis B infection; human papillomavirus infection; prostate cancer; and non-small cell lung cancer. The company also provides prophylactic programs for the prevention of herpes zoster and the Middle East respiratory syndrome. In addition, Vaccitech develops the COVID-19 vaccine.